Background
patent ductus arteriosus, RDS
RESPIRATORY DISTRESS SYNDROME
Respiratory distress syndrome (RDS) is a prevalent cause of morbidity and mortality in premature neonates [Normally, surfactant is present in the amniotic fluid from the 28th week of gestation, and its production depends on normal pH, temperature, and perfusion [So far, there are many studies that have evaluated the effect of natural and synthetic surfactants on RDS treatment [A clinical trial in the United States comparing the effect of survanta surfactant and curosurf in premature babies with an average gestational age of 26–29 weeks and an average weight of 1400 g, reported a decrease in supplemental oxygen in babies receiving curosurf as well as the prevalence of patent ductus arteriosus in babies receiving curosurf Compared to surventa, it was reported less with a statistically significant difference [Another clinical trial was conducted in Zika-free NICU of Turkey in infants less than 37 weeks gestational age from July 2008 to June 2009. 126 premature babies with RDS in two groups had similar basic demographic characteristics; In this study, the group receiving survanta surfactant required two or more doses compared to treatment with Corosurf; Also, extubation in the corosurf group was more within the first three days of drug administration, and the need for Fio2 after treatment on the first, third and fifth days was significantly lower in the corosurf group. Although the rate of mortality and morbidity of the two groups were similar, the findings of the study indicated an increase in the chance of survival in the corosurf group [This clinical trial study is designed to compare the effect of the Canadian BLES with the Iranian Survanta as an efficient surfactant.